{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:22Z","timestamp":1786119442544,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1097\/coc.0b013e3181a650d4","type":"journal-article","created":{"date-parts":[[2010,3,27]],"date-time":"2010-03-27T05:24:09Z","timestamp":1269667449000},"page":"246-250","source":"Crossref","is-referenced-by-count":10,"title":["A Phase II Study of Irinotecan With Biweekly, Low Dose Leucovorin and Bolus and Continuous Infusion 5-Fluorouracil (Modified FOLFIRI) as First Line Therapy For Patients With Recurrent or Metastatic Gastric Cancer"],"prefix":"10.1097","volume":"33","author":[{"given":"Byung Geun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuk-Chan","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Mee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Geun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Kyong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Chan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210128","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/annonc\/mdh422","article-title":"Palliative chemotherapy for advanced gastric cancer.","volume":"15","author":"Wohrer","year":"2004","journal-title":"Ann Oncol"},{"key":"R2-7-20210128","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3346\/jkms.1994.9.4.277","article-title":"Perspectives on stomach cancer.","volume":"9","author":"Chang","year":"1994","journal-title":"J Korean Med Sci"},{"key":"R3-7-20210128","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/jjco\/hym103","article-title":"A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.","volume":"37","author":"Kim","year":"2007","journal-title":"Jpn J Clin Oncol"},{"key":"R4-7-20210128","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/annonc\/mdl459","article-title":"Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).","volume":"18","author":"Pinto","year":"2007","journal-title":"Ann Oncol"},{"key":"R5-7-20210128","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","article-title":"Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.","volume":"24","author":"Wagner","year":"2006","journal-title":"J Clin Oncol"},{"key":"R6-7-20210128","first-page":"32","article-title":"Gastric adenocarcinoma\u2013management of the primary disease.","volume":"12","author":"Douglass","year":"1985","journal-title":"Semin Oncol"},{"key":"R7-7-20210128","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1002\/1097-0142(19930615)71:12<3813::AID-CNCR2820711205>3.0.CO;2-5","article-title":"A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.","volume":"71","author":"Kim","year":"1993","journal-title":"Cancer"},{"key":"R8-7-20210128","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1200\/JCO.1984.2.12.1372","article-title":"An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277).","volume":"2","author":"Douglass","year":"1984","journal-title":"J Clin Oncol"},{"key":"R9-7-20210128","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1200\/JCO.1986.4.9.1348","article-title":"Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies.","volume":"4","author":"Levi","year":"1986","journal-title":"J Clin Oncol"},{"key":"R10-7-20210128","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol"},{"key":"R11-7-20210128","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<295::AID-CNCR5>3.0.CO;2-H","article-title":"Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma.","volume":"85","author":"Kim","year":"1999","journal-title":"Cancer"},{"key":"R12-7-20210128","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/annonc\/mdh187","article-title":"5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial.","volume":"15","author":"Roth","year":"2004","journal-title":"Ann Oncol"},{"key":"R13-7-20210128","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/annonc\/mdh312","article-title":"Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial.","volume":"15","author":"Souglakos","year":"2004","journal-title":"Ann Oncol"},{"key":"R14-7-20210128","first-page":"5077","article-title":"Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.","volume":"49","author":"Hsiang","year":"1989","journal-title":"Cancer Res"},{"key":"R15-7-20210128","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/jnci\/86.11.836","article-title":"Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.","volume":"86","author":"Tanizawa","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"R16-7-20210128","first-page":"1033","article-title":"Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group [in Japanese].","volume":"21","author":"Futatsuki","year":"1994","journal-title":"Gan To Kagaku Ryoho"},{"key":"R17-7-20210128","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.bjc.6601226","article-title":"Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial.","volume":"89","author":"Kohne","year":"2003","journal-title":"Br J Cancer"},{"key":"R18-7-20210128","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/00001813-200309000-00010","article-title":"Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer.","volume":"14","author":"Moehler","year":"2003","journal-title":"Anticancer Drugs"},{"key":"R19-7-20210128","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/annonc\/mdh007","article-title":"Phase II study of irinotecan and 5-fluorouracil\/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.","volume":"15","author":"Assersohn","year":"2004","journal-title":"Ann Oncol"},{"key":"R20-7-20210128","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1023\/A:1013129315036","article-title":"A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.","volume":"12","author":"Blanke","year":"2001","journal-title":"Ann Oncol"},{"key":"R21-7-20210128","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000138352","article-title":"High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases?","volume":"74","author":"Ducreux","year":"2008","journal-title":"Oncology"},{"key":"R22-7-20210128","doi-asserted-by":"crossref","first-page":"8671","DOI":"10.1200\/JCO.2004.00.5686","article-title":"Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.","volume":"23","author":"Haller","year":"2005","journal-title":"J Clin Oncol"},{"key":"R23-7-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R24-7-20210128","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.1996.14.11.2959","article-title":"Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.","volume":"14","author":"Saltz","year":"1996","journal-title":"J Clin Oncol"},{"key":"R25-7-20210128","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.1999.17.9.2901","article-title":"Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.","volume":"17","author":"Ducreux","year":"1999","journal-title":"J Clin Oncol"},{"key":"R26-7-20210128","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.1997.15.2.808","article-title":"Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.","volume":"15","author":"de Gramont","year":"1997","journal-title":"J Clin Oncol"},{"key":"R27-7-20210128","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.coph.2006.05.002","article-title":"Determinants of chemosensitivity in gastric cancer.","volume":"6","author":"Park","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"R28-7-20210128","first-page":"2832","article-title":"Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5\u2032-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.","volume":"7","author":"Raida","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R29-7-20210128","doi-asserted-by":"crossref","first-page":"14402","DOI":"10.1016\/S0021-9258(18)68234-1","article-title":"Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells.","volume":"263","author":"Keyomarsi","year":"1988","journal-title":"J Biol Chem"},{"key":"R30-7-20210128","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0009-9236(99)70078-0","article-title":"Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.","volume":"65","author":"Iyer","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"R31-7-20210128","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2004.01.140","article-title":"Federation Francophone de Cancerologie Digestive Group Study\u2013FFCD 9803. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a.","volume":"22","author":"Bouche","year":"2004","journal-title":"J Clin Oncol"},{"key":"R32-7-20210128","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/annonc\/mdn166","article-title":"Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.","volume":"19","author":"Dank","year":"2008","journal-title":"Ann Oncol"},{"key":"R33-7-20210128","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000226486","article-title":"Carcinoembryonic antigen in gastric cancer patients.","volume":"44","author":"Shimizu","year":"1987","journal-title":"Oncology"},{"key":"R34-7-20210128","first-page":"181","article-title":"Carcinoembryonic antigen (CEA) plasma level determination in the management of gastric cancer patients.","volume":"8","author":"Dittrich","year":"1985","journal-title":"Cancer Detect Prev"},{"key":"R35-7-20210128","first-page":"3952","article-title":"Serum carcinoembryonic antigen level increases correlate with tumor progression in patients with differentiated gastric carcinoma following noncurative resection.","volume":"50","author":"Maehara","year":"1990","journal-title":"Cancer Res"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000421-201006000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:14:43Z","timestamp":1786040083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-201006000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e3181a650d4","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}